Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 1

Фармакотерапия кислотозависимых заболеваний желудочно-кишечного тракта с позиции выбора ингибитора протонной помпы
Г.Б. Селиванова, Н.Г. Потешкина

Список литературы

1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology 2013 Mar;108(3):308-28; quiz 329.
2. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008 Jan;336(7634):2-3.
3. Prescribing & Medicines Team, NHS Digital. Prescription Cost Analysis – England, 2018. NHS Digital responsible statistician: Ian Bullard. Available from: https://digital.nhs.uk/data-and-information/publications/ statistical/prescription-cost-analysis/2018 Accessed 2021 May 13.
4. Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B. Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Services Research 2015 Jan;15:11.
5. Осипенко М.Ф., Скалинская М.А., Ливзан М.А. Вопросы безопасности ингибиторов протонной помпы. Лечащий врач 2016;8:28-32.
6. Chan FKL, Lau JYW. Peptic ulcer disease. In: Sleisenger and Fordtran’s gastrointestinal and liver disease. Feldman M, Friedman L, Brandt L, editors. 2-vol. set. 10th ed. Philadelphia, PA: Saunders Elsevier; 2015: ch. 53.
7. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annual Review of Pharmacology and Toxicology 1995;35:277-305.
8. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatric Drugs 2003;5(1):25-40.
9. Блюме Х., Донат Ф., Варнке А., Шуг Б.С. Фармакокинетические лекарственные взаимодействия с участием ингибиторов протонной помпы. Русский медицинский журнал 2009;17(9):622-31.
10. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Current Gastroenterology Reports 2008 Dec;10(6):528-34.
11. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease – what are the unmet clinical needs? Alimentary Pharmacology & Therapeutics 2006 Jun;23(Suppl 2):9-22.
12. Лялюкова Е.А., Терещенко Ю.В., Чернышева Е.Н., Лялюков А.В. Выбор ингибитора протонной помпы с позиций эффективности и безопасности у конкретного пациента. Лечащий врач 2020;8:6-10.
13. Министерство здравоохранения РФ; Российская гастроэнтерологическая ассоциация; Российское общество колоректальных хирургов; Российское эндоскопическое общество. Язвенная болезнь. Клинические рекомендации. МКБ 10: K25/K26. Возрастная группа: взрослые. Год утверждения 2019. М., 37 с.
14. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2011 Jun;12(6):873-88.
15. Раскина К.В., Мартынова Е.Ю., Перфильев А.В., Сычев Д.А., Шуев Г.Н., Фатхутдинов И.Р., Мусиенко С.В., Никогосов Д.А., Жегулина И.О., Бавыкина Л.Г., Потешкин Ю.Е. От персонализированной к точной медицине. Рациональная фармакотерапия в кардиологии 2017;13(1):69-79.
16. U.S. Food & Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm Accessed 2021 May 13.
17. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics 2011 Mar;89(3):464-7.
18. Rouby NE, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018 Apr;14(4):447-60.
19. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GAPJM, van Schaik RHN, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ. Pharmacogenetics: from bench to byte – an update of guidelines. Clinical Pharmacology & Therapeutics 2011 May;89(5):662-73.
20. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011 Jan;12(1):113-24.
21. Lim PWY, Goh KL, Wong BCY. CYP2C19 genotype and the PPIs – focus on rabeprazole. Journal of Gastroenterology and Hepatology 2005 Dec;20(Suppl):S22-8.
22. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatric Drugs 2013 Apr;15(2):119-31.
23. НПП «Исток-Система». Функциональная гастроэнтерология. Цитохром Р450 (изоферменты CYP2C19 и CYP3A4). Доступно по: https://www.gastroscan.ru/handbook/117/3504 Ссылка активна на 13.05.2021.
24. Zou D, Goh KL. East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. Journal of Gastroenterology & Hepatology 2017 Jun;32(6):1152-9.
25. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. International Journal of Cardiology 2014 Nov;177(1):292-7.
26. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. European Journal of Clinical Pharmacology 2012 Sep;68(9):1267-74.
27. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clinical Pharmacology & Therapeutics 2004 Oct;76(4):290-301.
28. Lou HY, Chang CC, Sheu MT, Che YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. European Journal of Clinical Pharmacology 2009 Jan;65(1):55-64.
29. Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World Journal of Gastroenterology 2014 Jun;20(21):640-11.
30. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AZ, McCollam PL, Tomlin ME. Adherence and dosing frequency of common medications for cardiovascular patients. The American Journal of Managed Care 2012 Mar;18(3):139-46.
31. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. The American Journal of Gastroenterology 2007 May;102(5):942-50.
32. Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open 2020 Nov;10(11):e040473.
33. Hendrix I, Page AT, Korhonen MJ, Bell JS, Tan ECK, Visvanathan R, Cooper T, Robson L, Sluggett JK. Patterns of high-dose and long-term proton pump inhibitor use: a cross-sectional study in six South Australian residential aged care services. Drugs – Real World Outcomes 2019 Sep;6(3):105-13.
34. Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero C. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One 2018 Oct;13(10):e0204231.
35. Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies. Medicine 2019 Nov;98(44):e17788.
36. Douwes RM, Gomes-Neto AW, Eisenga MF, Vinke JSJ, de Borst MH, van den Berg E, Berger SP, Touw DJ, Hak E, Blokzijl H, Navis G, Bakker SJL. Chronic use of proton-pump inhibitors and iron status in renal transplant recipients. Journal of Clinical Medicine 2019 Sep;8(9):1382.
37. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole. Alimentary Pharmacology & Therapeutics 2004 Nov;20(Suppl 6):11-9.
38. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. European Journal of Clinical Pharmacology 2014 Sep;70(9):1073-8.
39. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP 2C19 genotypes. Alimentary Pharmacology & Therapeutics 2001 Jun;15(6):793-803.
40. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biological and Pharmaceutical Bulletin 2003 Mar;26(3):386-90.
41. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Alimentary Pharmacology & Therapeutics 2002 Oct;16(10):1811-7.
42. Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. European Journal of Clinical Pharmacology 2000 Dec;56(9-10):665-70.
43. Карева Е.Н. Рабепразол через призму «метаболизм-эффективность». Русский медицинский журнал 2016;17:1172-6.
44. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y. CYP 2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Alimentary Pharmacology & Therapeutics 2000 Oct;14(10):1259-66.

References

1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology 2013 Mar;108(3):308-28; quiz 329.
2. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008 Jan;336(7634):2-3.
3. Prescribing & Medicines Team, NHS Digital. Prescription Cost Analysis – England, 2018. NHS Digital responsible statistician: Ian Bullard. Available from: https://digital.nhs.uk/data-and-information/publications/ statistical/prescription-cost-analysis/2018 Accessed 2021 May 13.
4. Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B. Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Services Research 2015 Jan;15:11.
5. Osipenko MF, Skalinskaya MA, Livzan MA. Safety of proton pump inhibitors. Lechashchiy Vrach 2016;8:28-32 (In Russian).
6. Chan FKL, Lau JYW. Peptic ulcer disease. In: Sleisenger and Fordtran’s gastrointestinal and liver disease. Feldman M, Friedman L, Brandt L, editors. 2-vol. set. 10th ed. Philadelphia, PA: Saunders Elsevier; 2015: ch. 53.
7. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annual Review of Pharmacology and Toxicology 1995;35:277-305.
8. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatric Drugs 2003;5(1):25-40.
9. Blume HH, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Russian Medical Journal 2009;17(9):622-31 (In Russian).
10. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Current Gastroenterology Reports 2008 Dec;10(6):528-34.
11. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease – what are the unmet clinical needs? Alimentary Pharmacology & Therapeutics 2006 Jun;23(Suppl 2):9-22.
12. Lyalyukova EA, Tereshchenko YuV, Chernysheva EN, Lyalyukov AV. Choosing proton pump inhibitor: efficacy and safety for particular patient. Lechashchiy Vrach 2020;8:6-10 (In Russian).
13. Ministry of Healthcare of the Russian Federation. Russian Gastroenterological Association; Russian Society of Colorectal Surgeons; Russian Endoscopic Society. Peptic ulcer disease. Clinical recommendations. ICD 10: K25/K26. Age group: adults. Year of approval 2019. Moscow, 37 p. (In Russian).
14. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2011 Jun;12(6):873-88.
15. Raskina KV, Martynova EYu, Perfilyev AV, Sychev DA, Shuyev GN, Fatkhutdinov IR, Musiyenko SV, Nikogosov DA, Zhegulina IO, Bavykina LG, Poteshkin YuE. From personalized to precision medicine. Rational Pharmacotherapy in Cardiology 2017;13(1):69-79 (In Russian).
16. U.S. Food & Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm Accessed 2021 May 13.
17. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics 2011 Mar;89(3):464-7.
18. Rouby NE, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018 Apr;14(4):447-60.
19. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GAPJM, van Schaik RHN, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ. Pharmacogenetics: from bench to byte – an update of guidelines. Clinical Pharmacology & Therapeutics 2011 May;89(5):662-73.
20. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011 Jan;12(1):113-24.
21. Lim PWY, Goh KL, Wong BCY. CYP2C19 genotype and the PPIs – focus on rabeprazole. Journal of Gastroenterology and Hepatology 2005 Dec;20(Suppl):S22-8.
22. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatric Drugs 2013 Apr;15(2):119-31.
23. Scientific and production enterprise “Istok-Systema”. Functional gastroenterology. Cytochrome P450 (isoenzymes CYP2C19 and CYP3A4). Available from: https://www.gastroscan.ru/handbook/117/3504 Accessed 2021 May 13. (In Russian).
24. Zou D, Goh KL. East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. Journal of Gastroenterology & Hepatology 2017 Jun;32(6):1152-9.
25. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. International Journal of Cardiology 2014 Nov;177(1):292-7.
26. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. European Journal of Clinical Pharmacology 2012 Sep;68(9):1267-74.
27. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clinical Pharmacology & Therapeutics 2004 Oct;76(4):290-301.
28. Lou HY, Chang CC, Sheu MT, Che YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. European Journal of Clinical Pharmacology 2009 Jan;65(1):55-64.
29. Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World Journal of Gastroenterology 2014 Jun;20(21):640-11.
30. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AZ, McCollam PL, Tomlin ME. Adherence and dosing frequency of common medications for cardiovascular patients. The American Journal of Managed Care 2012 Mar;18(3):139-46.
31. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. The American Journal of Gastroenterology 2007 May;102(5):942-50.
32. Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open 2020 Nov;10(11):e040473.
33. Hendrix I, Page AT, Korhonen MJ, Bell JS, Tan ECK, Visvanathan R, Cooper T, Robson L, Sluggett JK. Patterns of high-dose and long-term proton pump inhibitor use: a cross-sectional study in six South Australian residential aged care services. Drugs – Real World Outcomes 2019 Sep;6(3):105-13.
34. Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero C. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One 2018 Oct;13(10):e0204231.
35. Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies. Medicine 2019 Nov;98(44):e17788.
36. Douwes RM, Gomes-Neto AW, Eisenga MF, Vinke JSJ, de Borst MH, van den Berg E, Berger SP, Touw DJ, Hak E, Blokzijl H, Navis G, Bakker SJL. Chronic use of proton-pump inhibitors and iron status in renal transplant recipients. Journal of Clinical Medicine 2019 Sep;8(9):1382.
37. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole. Alimentary Pharmacology & Therapeutics 2004 Nov;20(Suppl 6):11-9.
38. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. European Journal of Clinical Pharmacology 2014 Sep;70(9):1073-8.
39. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP 2C19 genotypes. Alimentary Pharmacology & Therapeutics 2001 Jun;15(6):793-803.
40. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biological and Pharmaceutical Bulletin 2003 Mar;26(3):386-90.
41. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Alimentary Pharmacology & Therapeutics 2002 Oct;16(10):1811-7.
42. Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. European Journal of Clinical Pharmacology 2000 Dec;56(9-10):665-70.
43. Kareva EN. Rabeprazole through the prism of “metabolism-efficiency”. Russian Medical Journal 2016;17:1172-6 (In Russian).
44. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y. CYP 2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Alimentary Pharmacology & Therapeutics 2000 Oct;14(10):1259-66.

  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]